Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAKUOH Study: Gardasil for prevention of persistent HPV16/18 infection in Japanese women aged 27–45
jRCTs051190039Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of qHPV vaccine in Cervical Cancer (CC), HPV16 infection (HPV16) and human papillomavirus infection (2 arms), sponsored by Merck & Co. Primary endpoint: Persistent infection rate (overall). Started Aug 2019; status: active, not recruiting.
02
Drugs
qHPV vaccine
03
Conditions
Cervical Cancer (CC)HPV16 infection (HPV16)human papillomavirus infection
Beyond the preview
Go deeper on jRCTs051190039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051190039.